Vimarsana
Biggest News Aggregation in the World

Page 4 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders - Vimarsana News

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales ...

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002 - Vimarsana News

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose

IP : STORM Therapeutics - Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -October 19, 2023 at 05:43 am EDT - Vimarsana News

IP : STORM Therapeutics - Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -October 19, 2023 at 05:43 am EDT

17 Oct 2023 STORM's first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase ...

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Vimarsana News

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA...

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ... - Vimarsana News

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ...

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors